LENZ Therapeutics (LENZ) Free Cash Flow: 2020-2024
Historic Free Cash Flow for Therapeutics (LENZ) over the last 5 years, with Dec 2024 value amounting to -$59.9 million.
- Therapeutics' Free Cash Flow rose 10.58% to -$21.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$60.4 million, marking a year-over-year increase of 36.12%. This contributed to the annual value of -$59.9 million for FY2024, which is 0.91% up from last year.
- Per Therapeutics' latest filing, its Free Cash Flow stood at -$59.9 million for FY2024, which was up 0.91% from -$60.4 million recorded in FY2023.
- Therapeutics' 5-year Free Cash Flow high stood at -$10.3 million for FY2020, and its period low was -$94.6 million during FY2022.
- Moreover, its 3-year median value for Free Cash Flow was -$60.4 million (2023), whereas its average is -$71.6 million.
- In the last 5 years, Therapeutics' Free Cash Flow tumbled by 470.74% in 2021 and then spiked by 36.12% in 2023.
- Yearly analysis of 5 years shows Therapeutics' Free Cash Flow stood at -$10.3 million in 2020, then plummeted by 470.74% to -$58.6 million in 2021, then slumped by 61.41% to -$94.6 million in 2022, then soared by 36.12% to -$60.4 million in 2023, then grew by 0.91% to -$59.9 million in 2024.